Akebia Ther (AKBA)

Currency in USD
1.550
-0.010(-0.64%)
Closed·
1.530-0.020(-1.29%)
·
AKBA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.5301.595
52 wk Range
1.1404.079
Key Statistics
Prev. Close
1.56
Open
1.57
Day's Range
1.53-1.595
52 wk Range
1.14-4.079
Volume
1.97M
Average Vol. (3m)
3.02M
1-Year Change
-17.9894%
Book Value / Share
0.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AKBA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.400
Upside
+183.87%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Akebia Ther News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Employees
194

Akebia Ther Earnings Call Summary for Q4/2025

  • Q4 EPS of -$0.05 missed forecast of $0.002 by 2600%; revenue beat at $57.6M vs $56.18M expected, up 23.9% YoY driven by Auryxia sales
  • Full-year 2025 revenue surged 47.4% to $236.2M; net loss improved 46.5% to $12.2M in Q4; cash position jumped 256.6% YoY to $184.8M
  • Stock rose 9.83% in premarket to $1.329 despite EPS miss; analysts maintain strong buy rating with $3-$6 price targets vs current $1.21
  • Company projects EPS of $0.02 in Q3 2026 and $0.04 in Q4 2026; FY 2026 revenue forecast at $289.3M as Vafseo launch continues
  • CEO Butler emphasized operational efficiency gains and R&D investment; risks include supply chain disruptions and regulatory hurdles
Last Updated: 02/26/2026, 08:53 AM
Read Full Transcript

Compare AKBA to Peers and Sector

Metrics to compare
AKBA
Peers
Sector
Relationship
P/E Ratio
−77.7x17.5x−0.5x
PEG Ratio
−0.790.090.00
Price / Book
12.7x4.5x2.6x
Price / LTM Sales
1.8x2.9x3.2x
Upside (Analyst Target)
156.4%92.5%47.6%
Fair Value Upside
Unlock13.6%6.1%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.400
(+183.87% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Buy3.00+93.55%-MaintainApr 14, 2026
H.C. Wainwright
Buy6.00+287.10%-MaintainApr 06, 2026
H.C. Wainwright
Buy6.00+287.10%-MaintainDec 02, 2025
H.C. Wainwright
Buy6.00+287.10%8.00MaintainOct 30, 2025
H.C. Wainwright
Buy8.00+416.13%-New CoverageJun 04, 2025

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.05 / 0.00
Revenue / Forecast
57.62M / 56.18M
EPS Revisions
Last 90 days

AKBA Income Statement

People Also Watch

38.790
HROW
+2.35%
10.320
ZVRA
+5.41%
7.78
IBRX
+2.37%
142.520
AAOI
-2.64%
2.460
CDXS
+3.80%

FAQ

What Is the Akebia Ther (AKBA) Stock Price Today?

The Akebia Ther stock price today is 1.550 USD.

What Stock Exchange Does Akebia Ther Trade On?

Akebia Ther is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Akebia Ther?

The stock symbol for Akebia Ther is "AKBA."

What Is the Akebia Ther Market Cap?

As of today, Akebia Ther market cap is 413.870M USD.

What Is Akebia Ther's Earnings Per Share (TTM)?

The Akebia Ther EPS (TTM) is -0.021.

When Is the Next Akebia Ther Earnings Date?

Akebia Ther will release its next earnings report on May 11, 2026.

From a Technical Analysis Perspective, Is AKBA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Akebia Ther Stock Split?

Akebia Ther has split 0 times.

How Many Employees Does Akebia Ther Have?

Akebia Ther has 194 employees.

What is the current trading status of Akebia Ther (AKBA)?

As of Apr 15, 2026, Akebia Ther (AKBA) is trading at a price of 1.550 USD, with a previous close of 1.560 USD. The stock has fluctuated within a day range of 1.530 USD to 1.595 USD, while its 52-week range spans from 1.140 USD to 4.079 USD.

What Is Akebia Ther (AKBA) Price Target According to Analysts?

The average 12-month price target for Akebia Ther is 4.400 USD, with a high estimate of 6 USD and a low estimate of 3 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +183.87% Upside potential.

What Is the AKBA Premarket Price?

AKBA's last pre-market stock price is 1.580 USD. The pre-market share volume is 6,500.000, and the stock has decreased by 0.020, or 1.280%.

What Is the AKBA After Hours Price?

AKBA's last after hours stock price is 1.530 USD, the stock has decreased by -0.020, or -1.290%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.